In both avacopan groups of Jayne et al., albuminuria decreased, and urinary creatinine-corrected monocyte chemoattractant protein-1 (MCP-1) levels improved significantly when compared to the control group at weeks 4 and 12 of the CLEAR (A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis) trial [25]. Here, CCL2 is linked to anti-neutrophil cytoplasmic antibody-associated vasculitis.